GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from E
GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from EGFR-directed therapy and that significantly more Asians than Russians had anenocarcinomas with mutated epidermal growth factor receptor. Baohui Han, MD PhD—a professor and oncologist from the Shanghai Chest Hospital—gave Oncology Times reporter Peter Goodwin details from IGNITE and also explained how a partner study—looking at erlotinib therapy for lung cancer in smokers, never smokers and women—revealed that patients with stage IIIA disease can be more effectively treated.